U et al.US FDA companion diagnostics co-development requirementan investigator-initiated trial (28) or previously undetected ALK
U et al.US FDA companion diagnostics co-development requirementan investigator-initiated trial (28) or previously undetected ALK rearrangement (41). Advances within the understanding of neoplastic illnesses couple with technical advancement inside the…